Market
What will be the outcome of the first AlphaFold AI drug clinical trial by end of 2026?
2
Google DeepMind•Demis Hassabis•AlphaFold AI•Hassabis•Isomorphic Labs•World Economic Forum•Davos•Eli Lilly•Novartis
Resolution / Starting Odds
Successful • 25%
Partially Successful • 25%
Unsuccessful • 25%
No Outcome Published • 25%
Official clinical trial results published by Isomorphic Labs or partner companies
Story
Google DeepMind's AlphaFold AI Drugs to Enter Clinical Trials by Year-End, Led by Nobel Prize Winner
Jan 24, 2025, 05:54 PM
Google DeepMind's CEO, Demis Hassabis, has announced that the company's AI-designed drugs, developed using the AlphaFold AI technology, are expected to enter clinical trials by the end of the year. These drugs target major therapeutic areas including cancer, heart disease, and neurodegenerative diseases. Hassabis, a Nobel Prize winner and leader of Isomorphic Labs, a Google DeepMind spinoff, stated that the AI technology aims to reduce the drug discovery process from a decade to weeks or months. The announcement was made during a panel at the World Economic Forum in Davos. Isomorphic Labs has already established strategic research collaborations with pharmaceutical giants Eli Lilly and Novartis to further this initiative.
View original story
Similar markets
Cancer treatment • 25%
Viral infections • 25%
Bacterial infections • 25%
Autoimmune diseases • 25%
Licensing Agreement • 25%
Phase 1 Clinical Trials • 25%
No further development • 25%
Partnership with NGO • 25%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worsening condition • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worse outcomes • 25%